Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

Size: px
Start display at page:

Download "Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier"

Transcription

1 Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name OMIM number for disease Disease alternative names Please provide any alternative names you wish listed Disease please provide a brief description of the disease characteristics Disease - mode of inheritance Kabuki syndrome KABUKI MAKE-UP SYNDROME; KMS NIIKAWA-KUROKI SYNDROME Kabuki syndrome is characterised by developmental delay / learning difficulties in association with a characteristic facial appearance, short stature and variable additional congenital malformations (e.g. cleft palate and congenital heart disease) and medical complications (e.g. neonatal hypoglycaemia, immune dysfunction and hypothyroidism). Autosomal dominant (usually de novo) Gene name(s) MLL2 OMIM number for gene(s) Gene alternative names ALR; MLL4; AAD10; KMT2B; KMT2D; TNRC21; CAGL114 Please provide any alternative names you wish listed Gene description(s) (including The MLL2 comprises 54 exons that are analysed in 78 amplicons number of amplicons) Mutational spectrum for which you test including details of known common mutations Point mutations and small insertions / deletions. No common mutations have been identified. At present it is unknown if large multi-exon deletions and duplications contribute significantly to the mutation spectrum of this gene. Technical Method (s) Bi-directional sequence analysis of MLL2. Analysis involves sequencing all exons and their intronic boundaries. Validation Process Note: please explain how this test has been validated for use in your laboratory Sequencing primers have been designed and optimised for all 78 amplicons. A panel of 60 individuals with suspected Kabuki syndrome and normal controls have been screened by sequence analysis. From this panel 35 / 60 (58%) have been found to have a mutation. This has also enabled us to identify common polymorphisms in MLL2. The laboratory also participates in all relevant technical EQA schemes that are available through UK NEQAS and EMQN: Genotypes correctly assigned in 3/3 sequencing EQA samples Genotypes correctly assigned in 3/3 sequencing EQA samples Genotypes correctly assigned in 3/3 sequencing EQA samples Genotypes correctly assigned in 4/4 sequencing EQA samples. 1

2 Are you providing this test already? If yes, how many reports have you produced? Please give the number of mutation positive/negative samples you have reported For how long have you been providing this service? Is there specialised local clinical/research expertise for this disease? Are you testing for other genes/diseases closely allied to this one? Please give details Your Current Activity If applicable - How many tests do you currently provide annually in your laboratory? Your Capacity if Gene Dossier approved How many tests will you be able to provide annually in your laboratory if this gene dossier is approved and recommended for NHS funding? Based on experience how many tests will be required nationally (UK wide)? National Activity (England, Scotland, Wales & Northern Ireland) If your laboratory is unable to provide the full national need please could you provide information on how the national requirement may be met For example, are you aware of any other labs (UKGTN members or otherwise) offering this test to NHS patients on a local area basis only? This question has been included In order to gauge if there could be any issues in equity of access for NHS patients. It is appreciated that some laboratories may not be able to answer this question. If this is the case please write unknown, offered on a research basis in 2010 during the validation process. If : Number of reports issued: 50 Number of reports mutation positive: 35 Number of reports mutation negative:15 6 months Please provide details Dr. Richard Scott, Consultant Clinical Geneticist, NE Thames Regional Genetics Service. No Index cases: 40 Family members where mutation is known: 50 Index cases: 50 Family members where mutation is known: 100 Index cases: 50 cases per year. Based on estimated incidence of 1 in 32,000 (Niikawa et al Am J Med Genet 1988;31:565-89). Family members where mutation is known: per year. Assuming 60-75% mutation detection rate (Ng et al. Nat Genet 2010;42:790-3 and Paulussen et al Hum Mutat Epub 2010) and potential unavailability of ~20% parents. Current practice would be to test both parents to confirm mutations are de novo. With additional experience, it may become unnecessary to test parents where the mutation is clearly pathogenic. The laboratory can provide a national service. We are aware that the Manchester Laboratory intends to offer this service to UKGTN. Together, our laboratories can meet the national requirement should it exceed the anticipated 50 index cases p.a. 2

3 Epidemiology Estimated prevalence of disease in the general UK population Estimated gene frequency (Carrier frequency or allele frequency) Estimated penetrance Target Population Description of the population to which this test will apply (i.e. description of the population as defined by the minimum criteria listed in the testing criteria) Estimated prevalence of disease in the target population 1 in 32,000 (estimated from retrospective hospital-based study; Niikawa et al Am J Med Genet 1988;31:565-89) 1 in 50,000 (based on estimated prevalence and current 60-75% estimated mutation frequency MLL2 (Ng et al Nat Genet 2010;42:790-3; Paulussen et al Hum Mutat Epub 2010). 100% (Ng et al Nat Genet 2010;42:790-3; Paulussen et al Hum Mutat Epub 2010) Individuals with a probable diagnosis of Kabuki syndrome (see diagnostic criteria below) based on the presence of: 1. characteristic facial appearance suggestive of Kabuki Syndrome Long palpebral fissures with eversion of the lateral portion of the lower eyelid Broad, arched eyebrows with lateral sparseness Short columella with depressed nasal tip Large, prominent or cupped ears. AND 2. developmental delay OR In newborns only: a combination of congenital abnormalities such that Kabuki Syndrome is the most likely diagnosis. Greater than 90%, with mutation frequency >50%. Intended Use (Please use the questions in Annex A to inform your answers) Please tick the relevant clinical purpose of testing Diagnosis Treatment Prognosis & Management Presymptomatic testing Risk Assessment for family members Risk Assessment prenatal testing YES No NO 3

4 Test Characteristics Analytical sensitivity and s pecificity This should be based on your own laboratory data for the specific test being applied for or the analytical sensitivity and specificity of the method/technique to be used in the case of a test yet to be set up Clinical sensitivity and specificity of test in target population The clinical sensitivity of a test is the probability of a positive test result when disease is known to be present; the clinical specificity is the probability of a negative test result when disease is known to be absent. The denominator in this case is the number with the disease (for sensitivity) or the number without disease (for specificity) Clinical validity (positive and negative predictive value in the target population) The clinical validity of a genetic test is a measure of how well the test predicts the presence or absence of the phenotype, clinical disease or predisposition. It is measured by its positive predictive value (the probability of getting the disease given a positive test) and negative predictive value (the probability of not getting the disease given a negative test) Testing pathway Please include your testing strategy if more than one gene will be tested and data on the expected proportions of positive results for each part of the process. Please illustrate this with a flow diagram. This can be added to the document as a separate sheet if necessary Clinical utility of test in target population (Please refer to Appendix A) Please provide a description of the clinical care pathway. Direct sequencing has a high sensitivity in this laboratory. We use Big Dye chemistry, ABI analysers (3130XL, 3730XL) and analyse using Mutation Surveyor software. We participate and perform successfully in EQA programmes for sequence analysis (see above). Bidirectional sequence analysis has specificity approaching 100% although large insertions/deletions and deep intronic mutations will not be detected. Clinical sensitivity currently estimated to be 60-75%. Clinical specificity is likely to be ~100% (Ng et al Nat Genet 2010;42:790-3; Paulussen et al Hum Mutat Epub 2010). Positive predictive value ~100% (Ng et al Nat Genet 2010;42:790-3; Paulussen et al Hum Mutat Epub 2010). Negative predictive value not relevant as the test will be used principally to confirm a clinical diagnosis. Bi-directional sequencing of all coding exons of MLL2. Utility of a positive test result: It allows confirmation of the clinical diagnosis and provides an explanation for the parents. It confirms applicability of the management guidelines ( es.pdf and Adam and Hudgins Clin Genet 2004l;67:209-19) and can therefore affect management of the child e.g. screening for cardiac and renal abnormalities and 4

5 How will the test add to the management of the patient or alter clinical outcome? ophthalmological examination for anterior chamber abnormalities and delayed visual maturation. It can alert the doctors managing the child to the possibility of rare complications such a biliary atresia, episodic idiopathic thrombocytopenic purpura It facilitates accurate genetic counselling confirming the low recurrence risk for Kabuki syndrome in which many cases are due to de novo mutations. This can be reassuring for parents though small risk of gonadal mosaicism remains allowing the option of prenatal diagnosis. This can be useful when parents are making future reproductive decisions. It helps parents to access support for education and social care. In the UK there is an informal network but an international organisation is based in Canada ( If the diagnosis is made it means that doctors can stop searching for other causes of learning disability and the patients are saved from having to undergo more investigations, many of which might be invasive In the case of KS there are specific benefits; It is an important early differential diagnosis of Rubinstein-Taybi syndrome. Also many patients with KS were previously investigated for chromosomal microdeletions with negative results or a rare recessive disorder such as Malpuech syndrome was considered. As a consequence they were given high/moderate recurrence risks for future pregnancies with no prospect of a test. Having the diagnosis of KS confirmed subsequently but excluded in the parents has meant that parents can be given very low recurrence risks and this can have a huge impact on reproductive decisions. Although this condition can be recognised clinically the phenotype is variable and often there is much discussion, even amongst experts, about mild cases or those with heights within the normal range. There are no other tests. Utility of a negative test result: will allow prioritisation of mutation negative cases for additional aetiological investigations including CGH array, other single gene analyses and research / exome studies aimed at identifying other genes causing Kabuki syndrome. In many cases of Kabuki syndrome, while the diagnosis is suspected, it cannot be made with certainty on clinical grounds. This often prevents the comprehensive application of the established clinical management guidelines ( df and Adam and Hudgins Clin Genet 2004l;67:209-19). This includes approaches that allow the identification of a number of associated disorders that might otherwise be missed (e.g. submucous cleft palate, hypothyroidism, immune dysfunction and subclinical hypoglycaemia). Molecular confirmation of the diagnosis in such cases will allow this. 5

6 What impact will this test have on the NHS i.e. by removing the need for alternative management and/or investigations for this clinical population? Please provide evidence from your own service What are the consequences of not doing this genetic test. Commissioners have asked for specific information to support introduction of tests Utility of test in the NHS In a couple of sentences explain the utility of this test for the disease(s) Is there an alternative means of diagnosis or prediction that does not involve molecular diagnosis? If so (and in particular if there is a biochemical test) please state the added advantage of the molecular test Please describe any specific ethical, legal or social issues with this particular test? In the case of positive test results, it will remove the need / cost of continued investigation of the underlying cause (including multiple clinical appointments, CGH array and other single gene analyses). It will also allow inclusion of affected individuals in tailored management guidelines (see above) and potentially reduce cost of follow-up of missed diagnosis of associated medical problems ( df and Adam and Hudgins Clin Genet 2004l;67:209-19). Failure to properly adhere to tailored management guidelines (see above) in clinically uncertain cases. This could lead to failure to identify associated medical disorders, e.g. submucous cleft palate, hypothyroidism, immune dysfunction and subclinical hypoglycaemia, and result in serious adverse outcomes. Confirms diagnosis that is often uncertain on clinical grounds. This allows (1) inclusion of clinically uncertain but proven cases in tailored management programme; (2) correct genetic counselling; (3) prenatal testing; (4) avoidance of unnecessary continued investigation of aetiology. No Diagnosis can be made clinically only in classical cases. N/A 6

7 UKGTN Testing Criteria Name of Disease(s): KABUKI SYNDROME 1; KABUK1 (147920) Name of gene(s): myeloid/lymphoid or mixed-lineage leukemia 2; MLL2 (602113) Patient name: Patient postcode: Date of birth: NHS number: Name of referrer: Title/Position: Lab ID: Referrals will only be accepted from one of the following: Referrer Consultant Clinical Geneticist Tick if this refers to you. Minimum criteria required for testing to be appropriate as stated in the Gene Dossier: Criteria Characteristic facial appearance suggestive of Kabuki Syndrome, e.g: Long palpebral fissures with eversion of the lateral portion of the lower eyelid Broad, arched eyebrows with lateral sparseness Short columella with depressed nasal tip Large, prominent or cupped ears. AND developmental delay OR In newborns only: a combination of congenital abnormalities such that Kabuki Syndrome is the most likely diagnosis. Tick if this patient meets criteria If the sample does not fulfil the clinical criteria or you are not one of the specified types of referrer and you still feel that testing should be performed please contact the laboratory to discuss testing of the sample. 7

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name OMIM number for disease 231300 Disease alternative names Please provide any alternative

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Epileptic encephalopathy, early infantile 4. OMIM number for disease 612164 Disease

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Loeys-Dietz Syndrome OMIM number for disease 609192; 608967; 610380; 610168 Disease

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Leber congenital amaurosis OMIM number for disease 204000 Disease alternative

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name HEMOCHROMATOSIS, TYPE 4; HFE4 OMIM number for disease #606069 Disease alternative

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Amyotrophic Lateral Sclerosis 10 (ALS10) and Amyotrophic Lateral Sclerosis 6 (ALS6)

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Genetic Causes of Hypothyroidism 1. Loss of function mutations in TSHR cause thyroid

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name and description (please provide any alternative names you wish listed) (A)-Testing

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Choroideremia OMIM number for disease 303100 Disease alternative names please

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Parkinson disease 8, automsomal dominant OMIM number for disease 607060 Disease

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name OMIM number for disease Disease alternative names please provide any alternative

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider TEST DISEASE/CONDITION POPULATION TRIAD Submitting laboratory: London North East RGC GOSH Approved: September

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name and description (please provide any alternative names Osteogenesis Imperfecta

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider TEST DISORDER/CONDITION POPULATION TRIAD Submitting laboratory: Exeter RGC Approved: Sept 2013 1. Disorder/condition

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name and description (please provide any alternative names you wish listed) (A)-Testing

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider TEST DISEASE/CONDITION POPULATION TRIAD Submitting laboratory: Manchester RGC Approved: September 2013

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider TEST DISEASE/CONDITION POPULATION TRIAD Submitting laboratory: Cambridge RGC Approved: September 2012

More information

Submitting Laboratory: London NE RGC GOSH

Submitting Laboratory: London NE RGC GOSH Submitting laboratory: London NE RGC GOSH 1. Disorder/condition approved name (please provide UK spelling if different from US) and symbol as published on the OMIM database (alternative names will be listed

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name and description (please provide any alternative names you wish listed) (A)-Testing

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name and description (please provide any alternative names you wish listed) (A)-Testing

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider TEST DISEASE/CONDITION POPULATION TRIAD Submitting laboratory: London North East RGC GOSH Approved: September

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name and description (please provide any alternative names you wish listed) Glucocorticoid-remediable

More information

Application to be an additional provider for existing test on the NHS Directory of Molecular Genetic Testing Additional Provider form

Application to be an additional provider for existing test on the NHS Directory of Molecular Genetic Testing Additional Provider form Application to be an additional provider for existing test on the NHS Directory of Molecular Genetic Testing Additional Provider form Disease: Gene: Cystic Fibrosis (CF) (carrier testing in reproductive

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Polycystic Kidney Disease, Autosomal Dominant OMIM number for disease 173900 Disease

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider TEST DISEASE/CONDITION POPULATION TRIAD Submitting laboratory: Birmingham RGC Approved: September 2012

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name and description (please provide any alternative names you wish listed) (A)-Testing

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name OMIM number for disease 312060 Disease alternative names please provide any alternative

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Submitting laboratory: Bristol RGC 1. Disorder/condition approved name and symbol as published on the OMIM database (alternative

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider TEST DISORDER/CONDITION POPULATION TRIAD Submitting laboratory: Cardiff SAS Porphyria Approved: Sept

More information

MLL2 mosaic mutations and intragenic deletion duplications in patients with Kabuki syndrome

MLL2 mosaic mutations and intragenic deletion duplications in patients with Kabuki syndrome Clin Genet 2013: 83: 467 471 Printed in Singapore. All rights reserved Short Report 2012 John Wiley & Sons A/S. Published by Blackwell Publishing Ltd CLINICAL GENETICS doi: 10.1111/j.1399-0004.2012.01955.x

More information

Approach to the Genetic Diagnosis of Neurological Disorders

Approach to the Genetic Diagnosis of Neurological Disorders Approach to the Genetic Diagnosis of Neurological Disorders Dr Wendy Jones MBBS MRCP Great Ormond Street Hospital for Children National Hospital for Neurology and Neurosurgery What is a genetic diagnosis?

More information

CURRENT GENETIC TESTING TOOLS IN NEONATAL MEDICINE. Dr. Bahar Naghavi

CURRENT GENETIC TESTING TOOLS IN NEONATAL MEDICINE. Dr. Bahar Naghavi 2 CURRENT GENETIC TESTING TOOLS IN NEONATAL MEDICINE Dr. Bahar Naghavi Assistant professor of Basic Science Department, Shahid Beheshti University of Medical Sciences, Tehran,Iran 3 Introduction Over 4000

More information

Genetic Counselling in relation to genetic testing

Genetic Counselling in relation to genetic testing Genetic Counselling in relation to genetic testing Dr Julie Vogt Consultant Geneticist West Midlands Regional Genetics Service September 2016 Disclosures for Research Support/P.I. Employee Consultant Major

More information

Practical challenges that copy number variation and whole genome sequencing create for genetic diagnostic labs

Practical challenges that copy number variation and whole genome sequencing create for genetic diagnostic labs Practical challenges that copy number variation and whole genome sequencing create for genetic diagnostic labs Joris Vermeesch, Center for Human Genetics K.U.Leuven, Belgium ESHG June 11, 2010 When and

More information

Introduction to Evaluating Hereditary Risk. Mollie Hutton, MS, CGC Certified Genetic Counselor Roswell Park Comprehensive Cancer Center

Introduction to Evaluating Hereditary Risk. Mollie Hutton, MS, CGC Certified Genetic Counselor Roswell Park Comprehensive Cancer Center Introduction to Evaluating Hereditary Risk Mollie Hutton, MS, CGC Certified Genetic Counselor Roswell Park Comprehensive Cancer Center Objectives Describe genetic counseling and risk assessment Understand

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Invasive Prenatal (Fetal) Diagnostic Testing File Name: Origination: Last CAP Review: Next CAP Review: Last Review: invasive_prenatal_(fetal)_diagnostic_testing 12/2014 3/2018

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider TEST DISORDER/CONDITION POPULATION TRIAD Submitting laboratory: Bristol RGC Approved: Sept 2013 1. Disorder/condition

More information

Challenges of CGH array testing in children with developmental delay. Dr Sally Davies 17 th September 2014

Challenges of CGH array testing in children with developmental delay. Dr Sally Davies 17 th September 2014 Challenges of CGH array testing in children with developmental delay Dr Sally Davies 17 th September 2014 CGH array What is CGH array? Understanding the test Benefits Results to expect Consent issues Ethical

More information

22q11.2 DELETION SYNDROME. Anna Mª Cueto González Clinical Geneticist Programa de Medicina Molecular y Genética Hospital Vall d Hebrón (Barcelona)

22q11.2 DELETION SYNDROME. Anna Mª Cueto González Clinical Geneticist Programa de Medicina Molecular y Genética Hospital Vall d Hebrón (Barcelona) 22q11.2 DELETION SYNDROME Anna Mª Cueto González Clinical Geneticist Programa de Medicina Molecular y Genética Hospital Vall d Hebrón (Barcelona) Genomic disorders GENOMICS DISORDERS refers to those diseases

More information

UKGTN Testing Criteria

UKGTN Testing Criteria UKGTN Testing Criteria Test name: Inherited Bone Marrow Failure Syndromes 44 Gene Panel Approved name disorder/(s): See Appendix 1 Approved name (s): See Appendix 1 (s): (s): Patient name: Patient postcode:

More information

Dysmorphology And The Paediatric Eye. Jill Clayton-Smith Manchester Centre For Genomic Medicine

Dysmorphology And The Paediatric Eye. Jill Clayton-Smith Manchester Centre For Genomic Medicine Dysmorphology And The Paediatric Eye Jill Clayton-Smith Manchester Centre For Genomic Medicine Why Make A Syndrome Diagnosis? Why did it happen? What does the future hold? How can you treat/manage it?

More information

Benefits and pitfalls of new genetic tests

Benefits and pitfalls of new genetic tests Benefits and pitfalls of new genetic tests Amanda Krause Division of Human Genetics, NHLS and University of the Witwatersrand Definition of Genetic Testing the analysis of human DNA, RNA, chromosomes,

More information

UKGTN Testing Criteria

UKGTN Testing Criteria Test name: Neonatal Diabetes 22 Gene Panel UKGTN Testing Criteria Approved name and symbol of disorder/condition(s): See Appendix 1 Approved name and symbol of gene(s): See Appendix 1 number(s): number(s):

More information

CHROMOSOMAL MICROARRAY (CGH+SNP)

CHROMOSOMAL MICROARRAY (CGH+SNP) Chromosome imbalances are a significant cause of developmental delay, mental retardation, autism spectrum disorders, dysmorphic features and/or birth defects. The imbalance of genetic material may be due

More information

SETPEG GENETIC TESTING GUIDELINES Version 1.0, 5 th October 2017

SETPEG GENETIC TESTING GUIDELINES Version 1.0, 5 th October 2017 SETPEG GENETIC TESTING GUIDELINES Version 1.0, 5 th October 2017 1. The Epilepsy Genetic Diagnostic & Counselling Service at King s Health Partners Professor Deb Pal PhD MRCP (Consultant) deb.pal@nhs.net

More information

Genetic Testing for Single-Gene and Multifactorial Conditions

Genetic Testing for Single-Gene and Multifactorial Conditions Clinical Appropriateness Guidelines Genetic Testing for Single-Gene and Multifactorial Conditions EFFECTIVE DECEMBER 1, 2017 Appropriate.Safe.Affordable 2017 AIM Specialty Health 2069-1217 Table of Contents

More information

JULY 21, Genetics 101: SCN1A. Katie Angione, MS CGC Certified Genetic Counselor CHCO Neurology

JULY 21, Genetics 101: SCN1A. Katie Angione, MS CGC Certified Genetic Counselor CHCO Neurology JULY 21, 2018 Genetics 101: SCN1A Katie Angione, MS CGC Certified Genetic Counselor CHCO Neurology Disclosures: I have no financial interests or relationships to disclose. Objectives 1. Review genetic

More information

Learning Outcomes: The following list provides the learning objectives that will be covered in the lectures, and tutorials of each week:

Learning Outcomes: The following list provides the learning objectives that will be covered in the lectures, and tutorials of each week: Course Code Course Title ECTS Credits MED-306 Medical Genetics 6 School Semester Prerequisites Medical School Spring (Semester 6) MED-103 Biology I MED-109 Biology II MED-204 Biochemistry I MED-209 Biochemistry

More information

Faravareh Khordadpoor (PhD in molecular genetics) 1- Tehran Medical Genetics Laboratory 2- Science and research branch, Islamic Azad University

Faravareh Khordadpoor (PhD in molecular genetics) 1- Tehran Medical Genetics Laboratory 2- Science and research branch, Islamic Azad University Faravareh Khordadpoor (PhD in molecular genetics) 1- Tehran Medical Genetics Laboratory 2- Science and research branch, Islamic Azad University 1395 21 مشاوره ژنتیک و نقش آن در پیش گیری از معلولیت ها 20

More information

MEDICAL GENOMICS LABORATORY. Next-Gen Sequencing and Deletion/Duplication Analysis of NF1 Only (NF1-NG)

MEDICAL GENOMICS LABORATORY. Next-Gen Sequencing and Deletion/Duplication Analysis of NF1 Only (NF1-NG) Next-Gen Sequencing and Deletion/Duplication Analysis of NF1 Only (NF1-NG) Ordering Information Acceptable specimen types: Fresh blood sample (3-6 ml EDTA; no time limitations associated with receipt)

More information

Specialised Services - Standards and Quality

Specialised Services - Standards and Quality Specialised Services - Standards and Quality Clinical Assurance Aim: to seek to provide assurance that the products of commissioning have clinical support from as broad a range of sectors and services

More information

This fact sheet describes the condition Fragile X and includes a discussion of the symptoms, causes and available testing.

This fact sheet describes the condition Fragile X and includes a discussion of the symptoms, causes and available testing. 11111 Fact Sheet 54 FRAGILE X SYNDROME This fact sheet describes the condition Fragile X and includes a discussion of the symptoms, causes and available testing. In summary Fragile X is a condition caused

More information

SNP Array NOTE: THIS IS A SAMPLE REPORT AND MAY NOT REFLECT ACTUAL PATIENT DATA. FORMAT AND/OR CONTENT MAY BE UPDATED PERIODICALLY.

SNP Array NOTE: THIS IS A SAMPLE REPORT AND MAY NOT REFLECT ACTUAL PATIENT DATA. FORMAT AND/OR CONTENT MAY BE UPDATED PERIODICALLY. SAMPLE REPORT SNP Array NOTE: THIS IS A SAMPLE REPORT AND MAY NOT REFLECT ACTUAL PATIENT DATA. FORMAT AND/OR CONTENT MAY BE UPDATED PERIODICALLY. RESULTS SNP Array Copy Number Variations Result: GAIN,

More information

SNP Array NOTE: THIS IS A SAMPLE REPORT AND MAY NOT REFLECT ACTUAL PATIENT DATA. FORMAT AND/OR CONTENT MAY BE UPDATED PERIODICALLY.

SNP Array NOTE: THIS IS A SAMPLE REPORT AND MAY NOT REFLECT ACTUAL PATIENT DATA. FORMAT AND/OR CONTENT MAY BE UPDATED PERIODICALLY. SAMPLE REPORT SNP Array NOTE: THIS IS A SAMPLE REPORT AND MAY NOT REFLECT ACTUAL PATIENT DATA. FORMAT AND/OR CONTENT MAY BE UPDATED PERIODICALLY. RESULTS SNP Array Copy Number Variations Result: LOSS,

More information

Genetic mates SNPedia write-ups Final Next-gen sequencing Mike Snyder QA: new technology and the future

Genetic mates SNPedia write-ups Final Next-gen sequencing Mike Snyder QA: new technology and the future Genetic mates SNPedia write-ups Final Next-gen sequencing Mike Snyder QA: new technology and the future Genetic Mates Jonathan Mortensen/Francisco Gimenez Will need class to upload data Tuesday night Analyze

More information

Genetic Testing 101: Interpreting the Chromosomes

Genetic Testing 101: Interpreting the Chromosomes Genetic Testing 101: Interpreting the Chromosomes Kristin Lindstrom, MD Division of Genetics and Metabolism Phoenix Children s Hospital AzAAP Pediatrics in the Red Rocks I have no disclosures for this

More information

Genomics for Rare Diseases

Genomics for Rare Diseases Genomics for Rare Diseases Gemma Chandratillake & Karola Rehnström East of England NHS Genomic Medicine Centre 21 st March 2018 Overview The genetic basis of rare disease Why is it useful to know the genetic

More information

110 DISEASES 3 DISEASES GENE TIC COUNSELING CARRIERMAP Recombine. Others. 30+ minute clinical genetic counseling session.

110 DISEASES 3 DISEASES GENE TIC COUNSELING CARRIERMAP Recombine. Others. 30+ minute clinical genetic counseling session. Recombine CARRIERMAP GENE TIC COUNSELING Genetic diseases, though individually rare, are collectively common; thus, assessing carrier status is one of the most important things you can do for your patients.

More information

Copy Number Variants of Uncertain Significance in Prenatal diagnosis Are the Goalposts Moving? Lisa Burvill-Holmes Bristol Genetics Laboratory

Copy Number Variants of Uncertain Significance in Prenatal diagnosis Are the Goalposts Moving? Lisa Burvill-Holmes Bristol Genetics Laboratory Copy Number Variants of Uncertain Significance in Prenatal diagnosis Are the Goalposts Moving? Lisa Burvill-Holmes Bristol Genetics Laboratory http://www.nbt.nhs.uk/genetics Microarray CGH in Prenatal

More information

Interpretation can t happen in isolation. Jonathan S. Berg, MD/PhD Assistant Professor Department of Genetics UNC Chapel Hill

Interpretation can t happen in isolation. Jonathan S. Berg, MD/PhD Assistant Professor Department of Genetics UNC Chapel Hill Interpretation can t happen in isolation Jonathan S. Berg, MD/PhD Assistant Professor Department of Genetics UNC Chapel Hill With the advent of genome-scale sequencing, variant interpretation is increasingly

More information

Genetics and Genomics: Applications to Developmental Disability

Genetics and Genomics: Applications to Developmental Disability Tuesday, 12:30 2:00, B1 Objective: Genetics and Genomics: Applications to Developmental Disability Helga Toriello 616-234-2712 toriello@msu.edu Identify advances in clinical assessment and management of

More information

Approach to Mental Retardation and Developmental Delay. SR Ghaffari MSc MD PhD

Approach to Mental Retardation and Developmental Delay. SR Ghaffari MSc MD PhD Approach to Mental Retardation and Developmental Delay SR Ghaffari MSc MD PhD Introduction Objectives Definition of MR and DD Classification Epidemiology (prevalence, recurrence risk, ) Etiology Importance

More information

Genetics/Genomics: role of genes in diagnosis and/risk and in personalised medicine

Genetics/Genomics: role of genes in diagnosis and/risk and in personalised medicine Genetics/Genomics: role of genes in diagnosis and/risk and in personalised medicine Lynn Greenhalgh, Macmillan Cancer and General Clinical Geneticist Cancer Genetics Service Cancer is common 1 in

More information

Genetics update and implications for (General) Practice

Genetics update and implications for (General) Practice Genetics update and implications for (General) Practice May 12 th 2018 Women s Health Symposium Clearwater Estate Dr Kate Gibson MB BCh, MRCP, FRACP Topics NZ Clinical Genetics delivery New Technologies

More information

Genetics Quality and Accreditation workshop Manchester 17 th May 2017

Genetics Quality and Accreditation workshop Manchester 17 th May 2017 Genetics Quality and Accreditation workshop Manchester 17 th May 2017 Katrina Rack Oxford CEQAS What is CEQAS Types of schemes Scheme update Highlights 2016 Key recommendations CEQAS Background External

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider Submitting laboratory: Leeds RGC 1. Disorder/condition approved name (please provide UK spelling if different

More information

UK National Screening Committee. Screening for Fragile X Syndrome in Pregnancy. 18 June 2015

UK National Screening Committee. Screening for Fragile X Syndrome in Pregnancy. 18 June 2015 UK National Screening Committee Screening for Fragile X Syndrome in Pregnancy 18 June 2015 Aim 1. This document provides background on the item addressing antenatal screening for Fragile X syndrome. Current

More information

Improving genomic diagnoses through accurate, specific phenotype information

Improving genomic diagnoses through accurate, specific phenotype information Improving genomic diagnoses through accurate, specific phenotype information Lisa Ewans Clinical Geneticist, RPAH, Sydney PhD student in genomics, KCCG, Garvan; UNSW https://vlab.org Overview Phenotype

More information

MOLECULAR DIAGNOSIS for X-LINKED INTELLECTUAL DISABILITY

MOLECULAR DIAGNOSIS for X-LINKED INTELLECTUAL DISABILITY MOLECULAR DIAGNOSIS for X-LINKED INTELLECTUAL DISABILITY Intellectual disability (ID) or mental retardation is characterized by significant limitations in cognitive abilities and social/behavioral adaptive

More information

Lab Activity Report: Mendelian Genetics - Genetic Disorders

Lab Activity Report: Mendelian Genetics - Genetic Disorders Name Date Period Lab Activity Report: Mendelian Genetics - Genetic Disorders Background: Sometimes genetic disorders are caused by mutations to normal genes. When the mutation has been in the population

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider Submitting laboratory: Sheffield RGC 1. Disorder/condition approved name (please provide UK spelling

More information

Committee Paper SCAAC(05/09)01. ICSI guidance. Hannah Darby and Rachel Fowler

Committee Paper SCAAC(05/09)01. ICSI guidance. Hannah Darby and Rachel Fowler Committee Paper Committee: Scientific and Clinical Advances Advisory Committee Meeting Date: 12 May 2009 Agenda Item: 4 Paper Number: SCAAC(05/09)01 Paper Title: ICSI guidance Author: Hannah Darby and

More information

Lab #10: Karyotyping Lab

Lab #10: Karyotyping Lab Lab #10: Karyotyping Lab INTRODUCTION A karyotype is a visual display of the number and appearance of all chromosomes from a single somatic cell. A normal human karyotype would reveal 46 chromosomes (22

More information

AMERICAN BOARD OF MEDICAL GENETICS AND GENOMICS

AMERICAN BOARD OF MEDICAL GENETICS AND GENOMICS AMERICAN BOARD OF MEDICAL GENETICS AND GENOMICS Logbook Guidelines for Certification in Clinical Genetics and Genomics for the 2017 Examination as of 10/5/2015 Purpose: The purpose of the logbook is to

More information

Information leaflet for Patients and families Germline Mosaicism

Information leaflet for Patients and families Germline Mosaicism Information leaflet for Patients and families Germline Mosaicism Introduction Germline mosaicism, also known as gonadal mosaicism, can explain why healthy parents sometimes have more than one child with

More information

Epilepsy Genetics Service Kings College Hospital & St Thomas s Hospital, London

Epilepsy Genetics Service Kings College Hospital & St Thomas s Hospital, London Epilepsy Genetics Service Kings College Hospital & St Thomas s Hospital, London Epilepsy Genetics Service Kings College Hospital & St Thomas s Hospital, London Epilepsy Genetics Team Professor Deb Pal

More information

Pedigree Analysis. A = the trait (a genetic disease or abnormality, dominant) a = normal (recessive)

Pedigree Analysis. A = the trait (a genetic disease or abnormality, dominant) a = normal (recessive) Pedigree Analysis Introduction A pedigree is a diagram of family relationships that uses symbols to represent people and lines to represent genetic relationships. These diagrams make it easier to visualize

More information

NGS Types of gene dossier applications UKGTN can evaluate

NGS Types of gene dossier applications UKGTN can evaluate NGS Types of gene dossier applications UKGTN can evaluate Jo Whittaker on behalf of the Genetic Test Evaluation Working Group & UKGTN Project team NGS used in a number of ways Replacement technology for

More information

CNNH NeuroGenomics Program Peer-to-Peer Service Consent/Information Form

CNNH NeuroGenomics Program Peer-to-Peer Service Consent/Information Form CNNH NeuroGenomics Program Peer-to-Peer Service Consent/Information Form WHO WEARE The Center for Neurological and Neurodevelopmental Health (CNNH) is an innovative patient- and family-centered "Specialty

More information

The University of Arizona Pediatric Residency Program. Primary Goals for Rotation. Genetics

The University of Arizona Pediatric Residency Program. Primary Goals for Rotation. Genetics The University of Arizona Pediatric Residency Program Primary Goals for Rotation Genetics 1. GOAL: Understand the role of the pediatrician in preventing genetic disease, and in counseling and screening

More information

What s the Human Genome Project Got to Do with Developmental Disabilities?

What s the Human Genome Project Got to Do with Developmental Disabilities? What s the Human Genome Project Got to Do with Developmental Disabilities? Disclosures Neither speaker has anything to disclose. Phase Two: Interpretation Officially started in October 1990 Goals of the

More information

Genetics and Genetic Testing for Autism:

Genetics and Genetic Testing for Autism: STAR Training 2/22/2018 Genetics and Genetic Testing for Autism: Demystifying the Journey to Find a Cause Alyssa (Ah leesa) Blesson, MGC, CGC Certified Genetic Counselor Center for Autism and Related Disorders

More information

CYSTIC FIBROSIS. The condition:

CYSTIC FIBROSIS. The condition: CYSTIC FIBROSIS Both antenatal and neonatal screening for CF have been considered. Antenatal screening aims to identify fetuses affected by CF so that parents can be offered an informed choice as to whether

More information

Atlas of Genetics and Cytogenetics in Oncology and Haematology

Atlas of Genetics and Cytogenetics in Oncology and Haematology Atlas of Genetics and Cytogenetics in Oncology and Haematology Genetic Counseling I- Introduction II- Motives for genetic counseling requests II-1. Couple before reproduction II-2. Couple at risk III-

More information

Genetic Testing for CHARGE Syndrome. Description

Genetic Testing for CHARGE Syndrome. Description Subject: Genetic Testing for CHARGE Syndrome Page: 1 of 9 Last Review Status/Date: December 2014 Genetic Testing for CHARGE Syndrome Description CHARGE syndrome is a rare genetic condition associated with

More information

CLINICAL HETEROGENEITY OF KABUKI SYNDROME: STUDY OF MOROCCAN PATIENTS

CLINICAL HETEROGENEITY OF KABUKI SYNDROME: STUDY OF MOROCCAN PATIENTS Int. J. LifeSc. Bt & Pharm. Res. 2012 S Nadifi et al., 2012 Research Paper ISSN 2250-3137 www.ijlbpr.com Vol.1, Issue. 1, January 2012 2012 IJLBPR. All Rights Reserved CLINICAL HETEROGENEITY OF KABUKI

More information

How many disease-causing variants in a normal person? Matthew Hurles

How many disease-causing variants in a normal person? Matthew Hurles How many disease-causing variants in a normal person? Matthew Hurles Summary What is in a genome? What is normal? Depends on age What is a disease-causing variant? Different classes of variation Final

More information

Precision Medicine and Genetic Counseling : Is Yes always the correct answer?

Precision Medicine and Genetic Counseling : Is Yes always the correct answer? Precision Medicine and Genetic Counseling : Is Yes always the correct answer? Beverly M. Yashar, MS, PhD, CGC Director, Graduate Program in Genetic Counseling Professor, Department of Human Genetics. (yashar@umich.edu)

More information

American Psychiatric Nurses Association

American Psychiatric Nurses Association Francis J. McMahon International Society of Psychiatric Genetics Johns Hopkins University School of Medicine Dept. of Psychiatry Human Genetics Branch, National Institute of Mental Health* * views expressed

More information

Case 1B. 46,XY,-14,+t(14;21)

Case 1B. 46,XY,-14,+t(14;21) Case 1B 46,XY,-14,+t(14;21) G-banded Chromosome telomere centromere G-dark bands AT-rich few genes G-pale bands GC-rich many genes telomere ideograms ideograms Conventional (light microscopy) p = short

More information

Could calcium and thyroid problems be related to a genetic condition?

Could calcium and thyroid problems be related to a genetic condition? Could calcium and thyroid problems be related to a genetic condition? Information for patients and families Reading this pamphlet can help you: Discover how having low calcium levels and thyroid problems

More information

Chapter 13. DiGeorge Syndrome

Chapter 13. DiGeorge Syndrome Chapter 13 DiGeorge Syndrome DiGeorge Syndrome is a primary immunodeficiency disease caused by abnormal migration and development of certain cells and tissues during fetal development. As part of the developmental

More information

The identification and management of heterozygous familial hypercholesterolaemia in adults, young people and children (QS41)

The identification and management of heterozygous familial hypercholesterolaemia in adults, young people and children (QS41) QS 41 The identification and management of heterozygous familial hypercholesterolaemia in adults, young people and children (QS41) NICE provided the content for this booklet which is independent of any

More information

MEDICAL GENOMICS LABORATORY. Non-NF1 RASopathy panel by Next-Gen Sequencing and Deletion/Duplication Analysis of SPRED1 (NNP-NG)

MEDICAL GENOMICS LABORATORY. Non-NF1 RASopathy panel by Next-Gen Sequencing and Deletion/Duplication Analysis of SPRED1 (NNP-NG) Non-NF1 RASopathy panel by Next-Gen Sequencing and Deletion/Duplication Analysis of SPRED1 (NNP-NG) Ordering Information Acceptable specimen types: Blood (3-6ml EDTA; no time limitations associated with

More information

Genetics of Hearing Loss

Genetics of Hearing Loss Genetics of Hearing Loss Daryl A. Scott MD/PhD Molecular & Human Genetics 1/20/2015 Why do we care? 1 100% 75% Hearing Loss 500:1000 50% 314:1000 25% 1:1000 17:1000 Newborn 18 yrs 65 yrs 75 yrs 60% Members

More information

Clinical evaluation of microarray data

Clinical evaluation of microarray data Clinical evaluation of microarray data David Amor 19 th June 2011 Single base change Microarrays 3-4Mb What is a microarray? Up to 10 6 bits of Information!! Highly multiplexed FISH hybridisations. Microarray

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider Submitting laboratory: Birmingham RGC 1. Disorder/condition approved name (please provide UK spelling

More information

Objectives. Genetics and Rett syndrome: As easy as apple pie! Chromosome to gene to protein

Objectives. Genetics and Rett syndrome: As easy as apple pie! Chromosome to gene to protein Genetics and Rett syndrome: As easy as apple pie! Victoria Mok Siu M.D., FRCPC, FCCMG ORSA conference Ottawa April 24, 2016 Objectives Review chromosomes and genes Understand s Explore the reasons behind

More information

New Advances in Psychiatric Genetics Joseph Shen, M.D., Ph.D. Aisha Furqan, LCGC Clinical Genetics UCSF-Fresno Community Regional Medical Center

New Advances in Psychiatric Genetics Joseph Shen, M.D., Ph.D. Aisha Furqan, LCGC Clinical Genetics UCSF-Fresno Community Regional Medical Center New Advances in Psychiatric Genetics Joseph Shen, M.D., Ph.D. Aisha Furqan, LCGC Clinical Genetics UCSF-Fresno Community Regional Medical Center Background Genetic testing Treatment options: Pharmacogenetics

More information

Chapter 7: Pedigree Analysis B I O L O G Y

Chapter 7: Pedigree Analysis B I O L O G Y Name Date Period Chapter 7: Pedigree Analysis B I O L O G Y Introduction: A pedigree is a diagram of family relationships that uses symbols to represent people and lines to represent genetic relationships.

More information